New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The accelerated approval is supported by results from part 1 of the ESSENCE trial
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
